Fig. 1From: Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective studyPatient disposition. TGC, tislelizumab plus gemcitabine and cisplatin; GC, gemcitabine and cisplatin; TRAEs, treatment-related adverse eventsBack to article page